Navigation Links
Kensey Nash Reports Second Quarter Fiscal Year 2011 Financial Results
Date:2/1/2011

e the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, St. Jude Medical's success in selling the Angio-Seal device and the extent to which, after December 31, 2010, St. Jude is able to and does in fact rely on its internal manufacturing to fulfill its requirements for collagen plugs for the Angio-Seal device, the success of the Company's customers and partners (including St. Jude Medical, Arthrex, Orthovita, Orteq and Synthes) in selling Kensey Nash related products in the marketplace, the Company's success in its research and development efforts (including in its cartilage repair, extracellular matrix and endovascular programs), the success of clinical trials in both the U.S. and outside the U.S. to support regulatory approval of the Company's products, and competition from other technologies, as well as tax and other risks associated with healthcare reform, economic conditions and foreign currency fluctuations. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings.  Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

– FINANCIAL INFORMATION TO FOLLOW –KENSEY NASH CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)Three MonthsSix MonthsEnded December 31, 2010Ended December 31, 20102010200920102009Revenues:Net salesBiomaterial sales

$
,630,328$   11,634,701$ 21,051,784$ 24,209,747Endovascular sales

269,333834,990727,8321,692,646Total net sales

10,899,66112,469,69121,779,61625,902,393Royalty income

6,455,2626,600,94112,539,90612,910,057Total revenues

17,354,92319,070,632
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
3. Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
4. Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products
5. Kensey Nash to Present at the 2009 UBS Global Life Sciences Conference
6. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
7. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
10. Pharmos Corporation Reports 2008 Second Quarter Results
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... , , , , , ... LOS ANGELES , Jan. 25 /PRNewswire-Asia/ -- ... the "Company"), is a leading manufacturer, distributor and,retailer of Chinese ... medical equipment in Northeastern,China . The Company today announced ...
... , Data Reported at the 2010 ... in Both Time to Tumor Progression and Overall Survival ... Capecitabine Arm , QUÉBEC CITY, Jan. 25 ... TSX: AEZ) (the "Company"), a late-stage drug development company ...
... devices, layers of atoms must be grown in neat, crystalline ... to develop bumps and defects a serious problem for ... the journal Science (Jan. 22, 2010), Cornell researchers ... films. Led by assistant professor of physics Itai Cohen, they ...
Cached Biology Technology:China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 2China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 3China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 4Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 2Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 3Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 4Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 5Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 6Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 7Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 8Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 9Watching crystals grow provides clues to making smoother, defect-free thin films 2
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... hundreds of proteins at once and enabling new experiments that ... has been invented by a team of University of Chicago ... , the new micro-western arrays combine the specificity of the ... DNA microarrays. The technique will allow scientists to observe much ...
... to many plant species. Plants attract insect pollinators with ... to ensure fertilization and reproduction. However, female moths are ... flower,s scent, they lay their eggs on the green ... the Max Planck Institute for Chemical Ecology have now ...
... 2010) Two recent, separate publications identified regions with higher ... in California. Using data collected by the California ... including almost 10,000 autism cases from 1996-2000, investigators at ... risk for autism. Autism Speaks, the nation,s largest autism ...
Cached Biology News:Illuminating protein networks in 1 step 2Illuminating protein networks in 1 step 3Changing flowering times protect tobacco plants against insect herbivory 2Changing flowering times protect tobacco plants against insect herbivory 3Changing flowering times protect tobacco plants against insect herbivory 4Autism Speaks responds to recent publications citing autism clusters in California 2
... enables fully automated hybridization of microarrays on ... been designed to offer researchers improved reproducibility, ... perform a wide range of applications. ... 485C; denaturations of up to 99C. The ...
... Fully automated microarray slide processing ... The trend to miniaturization, automation ... technology a powerful tool with many ... settings. These applications range from gene ...
... The user-friendly Eppendorf Thermomixer R offers ... that require shaking, heating, and cooling. ... expanded its application and temperature control ... each accommodate 24 micro test tubes, ...
... Blot Kits overcome this limitation and offer ... wide range in low-density protein array (96- ... are ideal for performing reverse-phase protein arrays ... the presence of low abundant antigens. Protein ...
Biology Products: